Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William B Capra

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Controlled Clinical Trials|March 17, 2004
Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpointsWilliam B Capra
Clinical Pharmacology and Therapeutics|July 28, 2019
Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled TrialsGillis Carrigan, Samuel Whipple, William B Capra, et al.
Pharmacoepidemiology and Drug Safety|March 16, 2019
An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records databaseGillis Carrigan, Samuel Whipple, Michael D Taylor, et al.
Health Services Research|May 15, 2018
Development and Validation of a High-Quality Composite Real-World Mortality EndpointMelissa D Curtis, Sandra D Griffith, Melisa Tucker, et al.
Contemporary Clinical Trials Communications|October 3, 2022
Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerationsW Katherine Tan, Brian D Segal, Melissa D Curtis, et al.
JCO Clinical Cancer Informatics|August 13, 2019
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data SetSandra D Griffith, Rebecca A Miksad, Geoff Calkins, et al.
Molecular Cancer Therapeutics|June 16, 2005
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumorsDavid E Weng, Paul A Masci, Susan F Radka, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Controlled Clinical Trials|March 17, 2004
Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpointsWilliam B Capra
Clinical Pharmacology and Therapeutics|July 28, 2019
Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled TrialsGillis Carrigan, Samuel Whipple, William B Capra, et al.
Pharmacoepidemiology and Drug Safety|March 16, 2019
An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records databaseGillis Carrigan, Samuel Whipple, Michael D Taylor, et al.
Health Services Research|May 15, 2018
Development and Validation of a High-Quality Composite Real-World Mortality EndpointMelissa D Curtis, Sandra D Griffith, Melisa Tucker, et al.
Contemporary Clinical Trials Communications|October 3, 2022
Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerationsW Katherine Tan, Brian D Segal, Melissa D Curtis, et al.
JCO Clinical Cancer Informatics|August 13, 2019
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data SetSandra D Griffith, Rebecca A Miksad, Geoff Calkins, et al.
Molecular Cancer Therapeutics|June 16, 2005
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumorsDavid E Weng, Paul A Masci, Susan F Radka, et al.
Pageof 1